Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Gross Profit (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Gross Profit for 6 consecutive years, with $84.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit rose 27.28% to $84.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $298.2 million, a 53.38% increase, with the full-year FY2025 number at $298.2 million, up 53.38% from a year prior.
  • Gross Profit was $84.3 million for Q4 2025 at GeneDx Holdings, roughly flat from $84.5 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $84.5 million in Q3 2025 to a low of -$29.6 million in Q2 2022.
  • A 5-year average of $27.0 million and a median of $22.0 million in 2023 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: tumbled 2442.78% in 2022, then soared 288.37% in 2023.
  • GeneDx Holdings' Gross Profit stood at -$2.8 million in 2021, then plummeted by 481.82% to -$16.3 million in 2022, then skyrocketed by 288.37% to $30.8 million in 2023, then surged by 115.27% to $66.2 million in 2024, then increased by 27.28% to $84.3 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Gross Profit are $84.3 million (Q4 2025), $84.5 million (Q3 2025), and $70.9 million (Q2 2025).